Is KYNB or ENLV more profitable?

Kyntra Bio has a net margin of 2,199.13% compared to Enlivex Therapeutics' net margin of 0.00%. Company Net Margins Return on Equity Return on Assets Kyntra Bio 2,199.13% N/A -47.27% Enlivex Therapeutics N/A N/A N/A

Which has preferable earnings & valuation, ATOS or ENLV?

Atossa Genetics is trading at a lower price-to-earnings ratio than Enlivex Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Atossa Genetics N/A N/A -$34.77M -$3.11 N/A Enlivex Therapeutics N/A N/A $1.24B -$8.25 N/A

Is ATOS or ENLV more profitable?

Enlivex Therapeutics' return on equity of 0.00% beat Atossa Genetics' return on equity. Company Net Margins Return on Equity Return on Assets Atossa Genetics N/A -102.99% -85.78% Enlivex Therapeutics N/A N/A N/A

Which has better valuation and earnings, ENLV or RADX?

Enlivex Therapeutics has higher earnings, but lower revenue than Radiopharm Theranostics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Enlivex Therapeutics N/A N/A $1.24B -$8.25 N/A Radiopharm Theranostics $1.88M 9.44 -$38.65M N/A N/A

Is ENLV or RADX more profitable?

Company Net Margins Return on Equity Return on Assets Enlivex Therapeutics N/A N/A N/A Radiopharm Theranostics N/A N/A N/A

Which has higher valuation and earnings, ENLV or JSPR?

Jasper Therapeutics is trading at a lower price-to-earnings ratio than Enlivex Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Enlivex Therapeutics N/A N/A $1.24B -$8.25 N/A Jasper Therapeutics N/A N/A -$75.80M -$1.59 N/A

Is ENLV or JSPR more profitable?

Enlivex Therapeutics' return on equity of 0.00% beat Jasper Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Enlivex Therapeutics N/A N/A N/A Jasper Therapeutics N/A -884.17% -143.83%

Enlivex Therapeutics (ENLV) Competitors

$0.26 +0.00 (+0.79%)

As of 01:06 PM Eastern

Compare

ENLV vs. KYNB, ATOS, TCRX, RADX, and JSPR

Should you buy Enlivex Therapeutics stock or one of its competitors? Enlivex Therapeutics's main competitors and comparable companies include Kyntra Bio (KYNB), Atossa Genetics (ATOS), TScan Therapeutics (TCRX), Radiopharm Theranostics (RADX), and Jasper Therapeutics (JSPR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Enlivex Therapeutics compare to Kyntra Bio?

Kyntra Bio (NASDAQ:KYNB) and Enlivex Therapeutics (NASDAQ:ENLV) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, dividends, risk, profitability, media sentiment, analyst recommendations and institutional ownership.

Kyntra Bio has a net margin of 2,199.13% compared to Enlivex Therapeutics' net margin of 0.00%.

Company	Net Margins	Return on Equity	Return on Assets
Kyntra Bio	2,199.13%	N/A	-47.27%
Enlivex Therapeutics	N/A	N/A	N/A

72.7% of Kyntra Bio shares are owned by institutional investors. Comparatively, 1.0% of Enlivex Therapeutics shares are owned by institutional investors. 4.2% of Kyntra Bio shares are owned by insiders. Comparatively, 12.3% of Enlivex Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Kyntra Bio has a beta of 1.05, indicating that its stock price is 5% more volatile than the broader market. Comparatively, Enlivex Therapeutics has a beta of 1.42, indicating that its stock price is 42% more volatile than the broader market.

In the previous week, Kyntra Bio had 1 more articles in the media than Enlivex Therapeutics. MarketBeat recorded 3 mentions for Kyntra Bio and 2 mentions for Enlivex Therapeutics. Kyntra Bio's average media sentiment score of 0.61 beat Enlivex Therapeutics' score of 0.41 indicating that Kyntra Bio is being referred to more favorably in the media.

Company	Overall Sentiment
Kyntra Bio	Positive
Enlivex Therapeutics	Neutral

Kyntra Bio presently has a consensus price target of $37.25, indicating a potential upside of 509.66%. Enlivex Therapeutics has a consensus price target of $247.50, indicating a potential upside of 97,340.94%. Given Enlivex Therapeutics' higher probable upside, analysts clearly believe Enlivex Therapeutics is more favorable than Kyntra Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kyntra Bio	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Enlivex Therapeutics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Enlivex Therapeutics has lower revenue, but higher earnings than Kyntra Bio. Enlivex Therapeutics is trading at a lower price-to-earnings ratio than Kyntra Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kyntra Bio	$6.44M	3.84	$183.45M	$45.30	0.13
Enlivex Therapeutics	N/A	N/A	$1.24B	-$8.25	N/A

Summary

Kyntra Bio beats Enlivex Therapeutics on 9 of the 14 factors compared between the two stocks.

How does Enlivex Therapeutics compare to Atossa Genetics?

Atossa Genetics (NASDAQ:ATOS) and Enlivex Therapeutics (NASDAQ:ENLV) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their risk, analyst recommendations, institutional ownership, earnings, valuation, dividends, profitability and media sentiment.

In the previous week, Atossa Genetics had 9 more articles in the media than Enlivex Therapeutics. MarketBeat recorded 11 mentions for Atossa Genetics and 2 mentions for Enlivex Therapeutics. Atossa Genetics' average media sentiment score of 0.89 beat Enlivex Therapeutics' score of 0.41 indicating that Atossa Genetics is being referred to more favorably in the media.

Company	Overall Sentiment
Atossa Genetics	Positive
Enlivex Therapeutics	Neutral

Atossa Genetics is trading at a lower price-to-earnings ratio than Enlivex Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atossa Genetics	N/A	N/A	-$34.77M	-$3.11	N/A
Enlivex Therapeutics	N/A	N/A	$1.24B	-$8.25	N/A

Enlivex Therapeutics' return on equity of 0.00% beat Atossa Genetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atossa Genetics	N/A	-102.99%	-85.78%
Enlivex Therapeutics	N/A	N/A	N/A

Atossa Genetics has a beta of 1.27, indicating that its share price is 27% more volatile than the broader market. Comparatively, Enlivex Therapeutics has a beta of 1.42, indicating that its share price is 42% more volatile than the broader market.

12.7% of Atossa Genetics shares are held by institutional investors. Comparatively, 1.0% of Enlivex Therapeutics shares are held by institutional investors. 9.8% of Atossa Genetics shares are held by company insiders. Comparatively, 12.3% of Enlivex Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Atossa Genetics presently has a consensus price target of $20.33, suggesting a potential upside of 733.33%. Enlivex Therapeutics has a consensus price target of $247.50, suggesting a potential upside of 97,340.94%. Given Enlivex Therapeutics' higher probable upside, analysts clearly believe Enlivex Therapeutics is more favorable than Atossa Genetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atossa Genetics	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20
Enlivex Therapeutics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Enlivex Therapeutics beats Atossa Genetics on 7 of the 13 factors compared between the two stocks.

How does Enlivex Therapeutics compare to TScan Therapeutics?

TScan Therapeutics (NASDAQ:TCRX) and Enlivex Therapeutics (NASDAQ:ENLV) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, profitability, valuation, institutional ownership, dividends, risk and earnings.

Enlivex Therapeutics has a net margin of 0.00% compared to TScan Therapeutics' net margin of -1,655.35%. Enlivex Therapeutics' return on equity of 0.00% beat TScan Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TScan Therapeutics	-1,655.35%	-108.72%	-54.47%
Enlivex Therapeutics	N/A	N/A	N/A

TScan Therapeutics currently has a consensus target price of $2.67, suggesting a potential upside of 1,020.45%. Enlivex Therapeutics has a consensus target price of $247.50, suggesting a potential upside of 97,340.94%. Given Enlivex Therapeutics' higher probable upside, analysts clearly believe Enlivex Therapeutics is more favorable than TScan Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TScan Therapeutics	1 Sell rating(s)	5 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.13
Enlivex Therapeutics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Enlivex Therapeutics has lower revenue, but higher earnings than TScan Therapeutics. TScan Therapeutics is trading at a lower price-to-earnings ratio than Enlivex Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TScan Therapeutics	$10.32M	1.56	-$129.77M	-$0.91	N/A
Enlivex Therapeutics	N/A	N/A	$1.24B	-$8.25	N/A

TScan Therapeutics has a beta of 1.15, suggesting that its stock price is 15% more volatile than the broader market. Comparatively, Enlivex Therapeutics has a beta of 1.42, suggesting that its stock price is 42% more volatile than the broader market.

In the previous week, Enlivex Therapeutics had 1 more articles in the media than TScan Therapeutics. MarketBeat recorded 2 mentions for Enlivex Therapeutics and 1 mentions for TScan Therapeutics. TScan Therapeutics' average media sentiment score of 1.82 beat Enlivex Therapeutics' score of 0.41 indicating that TScan Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
TScan Therapeutics	Very Positive
Enlivex Therapeutics	Neutral

82.8% of TScan Therapeutics shares are owned by institutional investors. Comparatively, 1.0% of Enlivex Therapeutics shares are owned by institutional investors. 6.3% of TScan Therapeutics shares are owned by insiders. Comparatively, 12.3% of Enlivex Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Enlivex Therapeutics beats TScan Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Enlivex Therapeutics compare to Radiopharm Theranostics?

Enlivex Therapeutics (NASDAQ:ENLV) and Radiopharm Theranostics (NASDAQ:RADX) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, media sentiment, institutional ownership, profitability, analyst recommendations, valuation and dividends.

In the previous week, Radiopharm Theranostics had 1 more articles in the media than Enlivex Therapeutics. MarketBeat recorded 3 mentions for Radiopharm Theranostics and 2 mentions for Enlivex Therapeutics. Radiopharm Theranostics' average media sentiment score of 0.61 beat Enlivex Therapeutics' score of 0.41 indicating that Radiopharm Theranostics is being referred to more favorably in the news media.

Company	Overall Sentiment
Enlivex Therapeutics	Neutral
Radiopharm Theranostics	Positive

1.0% of Enlivex Therapeutics shares are owned by institutional investors. 12.3% of Enlivex Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Enlivex Therapeutics has higher earnings, but lower revenue than Radiopharm Theranostics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enlivex Therapeutics	N/A	N/A	$1.24B	-$8.25	N/A
Radiopharm Theranostics	$1.88M	9.44	-$38.65M	N/A	N/A

Enlivex Therapeutics has a beta of 1.42, indicating that its stock price is 42% more volatile than the broader market. Comparatively, Radiopharm Theranostics has a beta of 1.78, indicating that its stock price is 78% more volatile than the broader market.

Enlivex Therapeutics currently has a consensus price target of $247.50, indicating a potential upside of 97,340.94%. Radiopharm Theranostics has a consensus price target of $11.00, indicating a potential upside of 873.45%. Given Enlivex Therapeutics' higher probable upside, equities research analysts clearly believe Enlivex Therapeutics is more favorable than Radiopharm Theranostics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enlivex Therapeutics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Radiopharm Theranostics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Company	Net Margins	Return on Equity	Return on Assets
Enlivex Therapeutics	N/A	N/A	N/A
Radiopharm Theranostics	N/A	N/A	N/A

Summary

Radiopharm Theranostics beats Enlivex Therapeutics on 6 of the 10 factors compared between the two stocks.

How does Enlivex Therapeutics compare to Jasper Therapeutics?

Enlivex Therapeutics (NASDAQ:ENLV) and Jasper Therapeutics (NASDAQ:JSPR) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, dividends, media sentiment, profitability, institutional ownership, analyst recommendations and risk.

Enlivex Therapeutics' return on equity of 0.00% beat Jasper Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Enlivex Therapeutics	N/A	N/A	N/A
Jasper Therapeutics	N/A	-884.17%	-143.83%

Enlivex Therapeutics presently has a consensus target price of $247.50, suggesting a potential upside of 97,340.94%. Jasper Therapeutics has a consensus target price of $7.33, suggesting a potential upside of 1,186.10%. Given Enlivex Therapeutics' higher probable upside, research analysts clearly believe Enlivex Therapeutics is more favorable than Jasper Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enlivex Therapeutics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Jasper Therapeutics	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.29

Jasper Therapeutics is trading at a lower price-to-earnings ratio than Enlivex Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enlivex Therapeutics	N/A	N/A	$1.24B	-$8.25	N/A
Jasper Therapeutics	N/A	N/A	-$75.80M	-$1.59	N/A

1.0% of Enlivex Therapeutics shares are held by institutional investors. Comparatively, 79.9% of Jasper Therapeutics shares are held by institutional investors. 12.3% of Enlivex Therapeutics shares are held by insiders. Comparatively, 3.9% of Jasper Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Enlivex Therapeutics has a beta of 1.42, indicating that its share price is 42% more volatile than the broader market. Comparatively, Jasper Therapeutics has a beta of 3.16, indicating that its share price is 216% more volatile than the broader market.

In the previous week, Jasper Therapeutics had 1 more articles in the media than Enlivex Therapeutics. MarketBeat recorded 3 mentions for Jasper Therapeutics and 2 mentions for Enlivex Therapeutics. Jasper Therapeutics' average media sentiment score of 0.54 beat Enlivex Therapeutics' score of 0.41 indicating that Jasper Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Enlivex Therapeutics	Neutral
Jasper Therapeutics	Positive

Summary

Jasper Therapeutics beats Enlivex Therapeutics on 7 of the 13 factors compared between the two stocks.

Get Enlivex Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ENLV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ENLV vs. The Competition

Export

Metric	Enlivex Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$4.48M	$3.92B	$7.24B	$13.22B
Dividend Yield	N/A	3.65%	2.53%	22.58%
P/E Ratio	-0.03	13.53	275.62	25.87
Price / Sales	N/A	1,176.76	580.40	79.65
Price / Cash	N/A	39.46	27.30	36.12
Price / Book	0.00	17.37	10.84	6.11
Net Income	$1.24B	-$22.69M	$3.50B	$380.72M
7 Day Performance	-29.28%	-2.80%	-1.85%	-2.16%
1 Month Performance	-73.32%	-8.97%	-4.63%	-4.09%
1 Year Performance	-98.52%	13.21%	6.16%	0.67%

Enlivex Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ENLV Enlivex Therapeutics	2.5432 of 5 stars	$0.26 +0.8%	$247.50 +96,579.7%	-98.5%	$4.48M	N/A	N/A	34	Short Interest Increase Gap Up
KYNB Kyntra Bio	3.7995 of 5 stars	$5.96 -2.1%	$37.25 +525.0%	N/A	$24.66M	$6.44M	0.13	570	Analyst Downgrade
ATOS Atossa Genetics	2.2348 of 5 stars	$2.45 flat	$20.33 +729.9%	-84.9%	$24.45M	N/A	N/A	14	News Coverage
TCRX TScan Therapeutics	3.751 of 5 stars	$0.28 -6.7%	$2.67 +868.3%	-89.2%	$20.01M	$10.32M	N/A	142	Positive News
RADX Radiopharm Theranostics	3.292 of 5 stars	$1.18 -7.1%	$11.00 +832.2%	-83.9%	$19.94M	$1.88M	N/A	14

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ENLV) was last updated on 10/12/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Enlivex Therapeutics (ENLV) Competitors

ENLV vs. KYNB, ATOS, TCRX, RADX, and JSPR

How does Enlivex Therapeutics compare to Kyntra Bio?

Summary

How does Enlivex Therapeutics compare to Atossa Genetics?

Summary

How does Enlivex Therapeutics compare to TScan Therapeutics?

Summary

How does Enlivex Therapeutics compare to Radiopharm Theranostics?

Summary

How does Enlivex Therapeutics compare to Jasper Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ENLV vs. The Competition

Enlivex Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Enlivex Therapeutics (ENLV) Competitors

ENLV vs. KYNB, ATOS, TCRX, RADX, and JSPR

How does Enlivex Therapeutics compare to Kyntra Bio?

Is KYNB or ENLV more profitable?

Do institutionals & insiders have more ownership in KYNB or ENLV?

Which has more risk & volatility, KYNB or ENLV?

Does the media prefer KYNB or ENLV?

Do analysts prefer KYNB or ENLV?

Which has higher earnings & valuation, KYNB or ENLV?

Summary

How does Enlivex Therapeutics compare to Atossa Genetics?

Does the media prefer ATOS or ENLV?

Which has preferable earnings & valuation, ATOS or ENLV?

Is ATOS or ENLV more profitable?

Which has more risk and volatility, ATOS or ENLV?

Do insiders and institutionals believe in ATOS or ENLV?

Do analysts prefer ATOS or ENLV?

Summary

How does Enlivex Therapeutics compare to TScan Therapeutics?

Is TCRX or ENLV more profitable?

Do analysts recommend TCRX or ENLV?

Which has stronger valuation and earnings, TCRX or ENLV?

Which has more risk and volatility, TCRX or ENLV?

Does the media refer more to TCRX or ENLV?

Do institutionals & insiders hold more shares of TCRX or ENLV?

Summary

How does Enlivex Therapeutics compare to Radiopharm Theranostics?

Does the media favor ENLV or RADX?

Do insiders & institutionals believe in ENLV or RADX?

Which has better valuation and earnings, ENLV or RADX?

Which has more risk and volatility, ENLV or RADX?

Do analysts recommend ENLV or RADX?

Is ENLV or RADX more profitable?

Summary

How does Enlivex Therapeutics compare to Jasper Therapeutics?

Is ENLV or JSPR more profitable?

Do analysts recommend ENLV or JSPR?

Which has higher valuation and earnings, ENLV or JSPR?

Do insiders and institutionals hold more shares of ENLV or JSPR?

Which has more risk & volatility, ENLV or JSPR?

Does the media refer more to ENLV or JSPR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ENLV vs. The Competition

Enlivex Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools